Combination therapy when metformin is not an option for type 2 diabetes.

about

Understanding and overcoming metformin gastrointestinal intolerance.Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.

P2860

Q30240030-A8340BEF-2E95-4C56-BD61-E376230BFE02 Q33665173-1FE61CAC-6B99-41A1-8826-D17DE50553AB

P2860

Combination therapy when metformin is not an option for type 2 diabetes.

Item

http://www.wikidata.org/entity/Q38377267

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Combination therapy when metformin is not an option for type 2 diabetes.

@en

type

Item

label

Combination therapy when metformin is not an option for type 2 diabetes.

@en

prefLabel

Combination therapy when metformin is not an option for type 2 diabetes.

@en

P1476

Combination therapy when metformin is not an option for type 2 diabetes.

@en

P2093

Jennifer D Goldman-Levine

http://www.w3.org/2001/XMLSchema#string

P2860

Use of metformin in the setting of mild-to-moderate renal insufficiency

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

P304

688-699

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028015572653

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273522354

http://www.w3.org/2001/XMLSchema#string

P698

25770115

http://www.w3.org/2001/XMLSchema#string

P921

metformin

Combination therapy when metformin is not an option for type 2 diabetes.

about

P2860

P2860

Combination therapy when metformin is not an option for type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921